The seed round was backed by ACF Investors, o2h Ventures, and angel investors to fund team expansion and platform development.
"With this investment, our investors have affirmed the strength of our technology and its commercial potential. Building upon years of research, this funding will drive the development of our platform, facilitate the rollout of our own range of therapeutics and expand our team. As our recent collaboration with the UCL Drug Discovery Institute has shown, we are beginning to have a potent effect on the pharmaceutical industry and I am looking forward to the many ways in which we can make a decisive contribution to medicine worldwide"
The funding was provided by o2h Ventures to back the University of Sussex spin out.
"We are delighted to be working with the University of Sussex and the founders to launch and grow Stingray Bio. We have been following the science for several years and we are now excited to support the commercialisation of the founder's research to develop new drugs for cancer."
The biotechnology spin-out raised funds from backers including the Angel CoFund and o2h Ventures alongside Department of Health and Social Care grants.
"This latest funding further validates our computational design-led focus that has enabled rapid progress in building our pipeline of novel antibiotic programmes."
